Your browser doesn't support javascript.
loading
Pharmacoeconomics Evaluation of CYP2C19 Genetic Test Guiding Antiplatelet Therapy for Acute Coro-nary Syndrome Patients in China / 中国药房
China Pharmacy ; (12): 3183-3187, 2017.
Article in Chinese | WPRIM | ID: wpr-612260
ABSTRACT

OBJECTIVE:

To evaluate the feasibility of using CYP2C19 gene to guide the use of antiplatelet agents in acute cor-onary syndrome(ACS)patients undergoing interventional operation in China from the viewpoint of pharmacoeconomics. METH-ODSBased on global PLATO trial data,the patients were divided into 3 groups according to treatment strategies(clopidogrel group,ticagrelor group,genetic test group). By applying Treeage Pro 2011 software,short-term decision tree model and long-term Markov model were established,and related data were imported to evaluate cost-effectiveness of different treatment strategies. RE-SULTS&

CONCLUSIONS:

For ACS patients,according to the level of GDP in China,conventional use of ticagrelor is of pharma-coeconomic advantage for in Shanghai and uninsured patients insured patients;the use of antiplatelet agents guided by CYP2C19 gene test is of pharmacoeconomic advantage among nationwide insured patients.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Health economic evaluation / Prognostic study Language: Chinese Journal: China Pharmacy Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Health economic evaluation / Prognostic study Language: Chinese Journal: China Pharmacy Year: 2017 Type: Article